Amgenvs.BioMarin Pharmaceutical
AMGN vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 17× larger than BioMarin Pharmaceutical by market cap; Amgen trades at the lower P/E (25.1 vs 42.6); year to date, Amgen leads (+11.0% vs −0.5%).
Side by side
| AMGN | BMRN | |
|---|---|---|
| Market cap | $196B | $11.4B |
| Price | $363.39 | $59.12 |
| Today | −0.1% | −1.4% |
| Return YTD | +11.0% | −0.5% |
| Return 1Y | +21.0% | +0.5% |
| P/E | 25.1 | 42.6 |
| P/S | 5.3 | 3.5 |
| P/B | 21.3 | 1.8 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →More comparisons in Biotech & innovation
See where AMGN and BMRN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →